<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955500</url>
  </required_header>
  <id_info>
    <org_study_id>PR(HG)61/2002</org_study_id>
    <nct_id>NCT00955500</nct_id>
  </id_info>
  <brief_title>Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy</brief_title>
  <official_title>Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a normal-protein diet containing branched-chain amino&#xD;
      acids to a low-protein diet in patients with non-terminal cirrhosis (MELD &lt; 25) who have&#xD;
      developed an episode of hepatic encephalopathy within two months prior to inclusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy is a major complication of cirrhosis associated with poor prognosis&#xD;
      and poor quality of life. Appearance of HE occurs in the setting of precipitating factors&#xD;
      that increase plasma ammonia. The gastrointestinal tract is the primary source of ammonia,&#xD;
      which is produced by enterocytes from glutamine and by colonic bacterial catabolism of&#xD;
      nitrogenous sources, such as ingested proteins. This is the rationale for proposing&#xD;
      low-protein diet as strategy to reduce ammonia production and as standard diet in patients&#xD;
      with cirrhosis and hepatic encephalopathy. However, low-protein diet could cause wasting&#xD;
      muscle and predispose to recurrence of hepatic encephalopathy, since muscle is an important&#xD;
      site for extrahepatic ammonia removal.&#xD;
&#xD;
      Branched-chain amino acids have shown beneficial effects on mental state of patients with&#xD;
      chronic hepatic encephalopathy. The possible mechanism of action may be improvement of&#xD;
      nutritional status through induction of protein synthesis. However, role of branched-chain&#xD;
      amino acids in treatment and prevention of acute hepatic encephalopathy is not established.&#xD;
&#xD;
      Administration of a normal-protein diet containing oral branched-chain amino acids may reduce&#xD;
      recurrence of hepatic encephalopathy as compared to a low-protein diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic encephalopathy-free survival</measure>
    <time_frame>56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall duration in days of episodic hepatic encephalopathy</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal hepatic encephalopathy assessed by neuropsychological tests</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Normal-protein diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-protein diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Branched-chain amino acids</intervention_name>
    <description>30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily</description>
    <arm_group_label>Normal-protein diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>30 grams of oral maltodextrin daily</description>
    <arm_group_label>Low-protein diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis of the liver.&#xD;
&#xD;
          -  Recovery from an episode of hepatic encephalopathy within two months prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Compliance with a standard diet during two weeks prior to inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  End-stage cirrhosis (MELD score &gt; 25).&#xD;
&#xD;
          -  Marked cognitive disorder (mini-mental test &lt; 27).&#xD;
&#xD;
          -  Non-treatable hepatocarcinoma in accordance with Milan criteria.&#xD;
&#xD;
          -  Comorbid conditions with a life expectancy less than 6 months.&#xD;
&#xD;
          -  Neurological conditions that difficult assessment of treatment of hepatic&#xD;
             encephalopathy (dementia, encephalitis, severe depression).&#xD;
&#xD;
          -  Diseases requiring administration of a specific diet (malabsorption, chronic diarrhea,&#xD;
             chronic pancreatic insufficiency, severe obesity).&#xD;
&#xD;
          -  No acceptation of written consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Córdoba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>August 7, 2009</last_update_submitted>
  <last_update_submitted_qc>August 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Juan Córdoba, MD</name_title>
    <organization>Hospital Universitari Vall d´Hebron</organization>
  </responsible_party>
  <keyword>Hepatic encephalopathy</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Proteins of the diet</keyword>
  <keyword>Branched-chain amino acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

